Next Article in Journal
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
Next Article in Special Issue
Filling the Gap: Neural Stem Cells as A Promising Therapy for Spinal Cord Injury
Previous Article in Journal
Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System
Open AccessReview

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

by 1 and 1,2,*
1
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2
Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4450-208 Matosinhos, Portugal
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(1), 41; https://doi.org/10.3390/ph12010041
Received: 15 February 2019 / Revised: 13 March 2019 / Accepted: 15 March 2019 / Published: 19 March 2019
(This article belongs to the Special Issue Therapeutics Agents for Neural Repair)
Alzheimer’s disease (AD) is a growing global health concern with a massive impact on affected individuals and society. Despite the considerable advances achieved in the understanding of AD pathogenesis, researchers have not been successful in fully identifying the mechanisms involved in disease progression. The amyloid hypothesis, currently the prevalent theory for AD, defends the deposition of β-amyloid protein (Aβ) aggregates as the trigger of a series of events leading to neuronal dysfunction and dementia. Hence, several research and development (R&D) programs have been led by the pharmaceutical industry in an effort to discover effective and safety anti-amyloid agents as disease modifying agents for AD. Among 19 drug candidates identified in the AD pipeline, nine have their mechanism of action centered in the activity of β or γ-secretase proteases, covering almost 50% of the identified agents. These drug candidates must fulfill the general rigid prerequisites for a drug aimed for central nervous system (CNS) penetration and selectivity toward different aspartyl proteases. This review presents the classes of γ-secretase and beta-site APP cleaving enzyme 1 (BACE-1) inhibitors under development, highlighting their structure-activity relationship, among other physical-chemistry aspects important for the successful development of new anti-AD pharmacological agents. View Full-Text
Keywords: Alzheimer’s disease; amyloid hypothesis; γ-secretase; BACE-1 Alzheimer’s disease; amyloid hypothesis; γ-secretase; BACE-1
Show Figures

Figure 1

MDPI and ACS Style

Maia, M.A.; Sousa, E. BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease. Pharmaceuticals 2019, 12, 41. https://doi.org/10.3390/ph12010041

AMA Style

Maia MA, Sousa E. BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease. Pharmaceuticals. 2019; 12(1):41. https://doi.org/10.3390/ph12010041

Chicago/Turabian Style

Maia, Miguel A.; Sousa, Emília. 2019. "BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease" Pharmaceuticals 12, no. 1: 41. https://doi.org/10.3390/ph12010041

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop